Bionomics Ltd., of Adelaide, Australia, said the FDA has cleared BNC101, a first-in-class, high-affinity humanized monoclonal antibody targeting cancer stem cells, to start clinical trials. The company said it plans to begin a phase I study in those with metastatic colon cancer and metastatic pancreatic cancer before Dec. 31.